Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Carlo Rizzuto
AddedMar 31, 2024
UpdatedMay 31, 2026
Carlo Rizzuto

Carlo Rizzuto

Board Member, Quentis Therapeutics

Crunchbase

Carlo Rizzuto's Career

Quentis Therapeutics
Quentis Therapeutics

New York City, NY, US

Board Member· Board
Venatorx Pharmaceuticals
Venatorx Pharmaceuticals

Malvern, PA, US

Board Member· Board
Jnana Therapeutics
Jnana Therapeutics

Boston, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Carlo Rizzuto's Career

Quentis Therapeutics
Quentis Therapeutics
Pre-Seed$49M302016New York City, NY, US
Board Member· Board

Leadership at Quentis Therapeutics

Sarah BettigoleSarah BettigoleCo-Founder
Laurie GlimcherLaurie GlimcherCo-Founder
Michael AbermanMichael AbermanCEO
Mark MurckoMark MurckoBoard Member
Juan Cubillos-RuizJuan Cubillos-RuizCo-Founder

Similar to Quentis Therapeutics

Q32 BioQ32 BioWaltham, MA, USBiotherapeuticsest. 2017Q32 BioWaltham, MA, US · est. 2017

Q32 Bio is a biotech firm developing therapies to balance the immune system in severe autoimmune diseases.

Series B · $106M44
Quanta TherapeuticsQuanta TherapeuticsSan Francisco, CA, USCancer Therapeuticsest. 2018Quanta TherapeuticsSan Francisco, CA, US · est. 2018

Quanta, founded in 2018, is a San Francisco-based biotech firm specializing in novel cancer therapeutics.

Series D · $140.7M28
Therini BioTherini BioSouth San Francisco, CA, USImmunotherapies, Therapeuticsest. 2016Therini BioSouth San Francisco, CA, US · est. 2016

Therini Bio, Inc.: Innovating neuroinflammatory treatments through biotechnological research and development.

Series A · $65.3M17
Q TherapeuticsQ TherapeuticsSalt Lake City, UT, USCell Therapiesest. 2005Q TherapeuticsSalt Lake City, UT, US · est. 2005

Q Therapeutics, Inc., a Salt Lake City-based company, develops cell-based treatments for neurological disorders.

Series A · $24.2M5
Venatorx Pharmaceuticals
Venatorx Pharmaceuticals
Series B$165.7M812010Malvern, PA, US
Board Member· Board

Leadership at Venatorx Pharmaceuticals

Daniel C. PevearDaniel C. PevearCo-Founder
Tomas J. HeymanTomas J. HeymanBoard Member
Brett ZbarBrett ZbarBoard Member
Shelley ChuShelley ChuBoard Member
Luigi XerriLuigi XerriCo-Founder
Christopher J. BurnsChristopher J. BurnsCo-Founder
Jnana Therapeutics
Jnana Therapeutics
Series C$207M922016Boston, MA, US
Board Member· Board

Leadership at Jnana Therapeutics

Matthew HammondMatthew HammondBoard Member
Amir NashatAmir NashatBoard Member
Brian CaliBrian CaliBoard Member
Stuart SchreiberStuart SchreiberBoard Member
Joanne KotzJoanne KotzCo-Founder
Joel BarrishJoel BarrishCo-Founder

Carlo Rizzuto's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoSean JohSean JohBoard Member · Kakao

People Similar to Carlo Rizzuto

Ronald LennoxRonald LennoxBoard Member · BiorelixFabrizio BonanniFabrizio BonanniBoard Member · TheranosJonathan RootJonathan RootBoard Member · Inari MedicalReggie GrovesReggie GrovesBoard Member · Advanced NanoTherapiesRajeev ShahRajeev ShahBoard Member · Solid BiosciencesFabio PucciFabio PucciBoard Member · Indapta Therapeutics